Norethisterone enanthate
 |
|
| Clinical data | |
|---|---|
| Trade names | Noristerat, Norigest, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
intramuscular injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| Synonyms | SH-393 |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| ECHA InfoCard | 100.021.207 |
| Chemical and physical data | |
| Formula | C27H38O3 |
| Molar mass | 410.588 g/mol |
  (what is this?)
|
|
Norethisterone enanthate (NET-EN), also known as norethindrone enanthate, is a form of progestogen-only injectable birth control. It may be used following childbirth, miscarriage, or abortion. The failure rate per year is 2 per 100 women. Each dose lasts two months with up to two doses recommended.
Side effects may include breast pain, headaches, depression, irregular menstrual periods, and pain at the site of injection. Use in those with liver disease or during pregnancy is not recommended. Use appears to be okay during breastfeeding. It does not protect against sexually transmitted infections. Norethisterone enanthate is an ester of norethisterone, by which it works. It works by stopping ovulation.
Norethisterone was patented in 1951 and came into medical use in 1957. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 1.04 to 7.99 USD per 200 mg vial. It has been approved in more than 40 countries including the United Kingdom and some in Europe, Central America, and Africa. It is not available in the United States.
It is a steroidal progestin of the 19-nortestosterone group with additional weak androgenic and estrogenic activity
...
Wikipedia